TY - JOUR
T1 - Uremic Toxins and Vascular Calcification-Missing the Forest for All the Trees
AU - Rapp, Nikolas
AU - Evenepoel, Pieter
AU - Stenvinkel, Peter
AU - Schurgers, Leon
N1 - Funding Information:
Funding: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska‐Curie grant agreement No 764474.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
PY - 2020/10
Y1 - 2020/10
N2 - The cardiorenal syndrome relates to the detrimental interplay between the vascular system and the kidney. The uremic milieu induced by reduced kidney function alters the phenotype of vascular smooth muscle cells (VSMC) and promotes vascular calcification, a condition which is strongly linked to cardiovascular morbidity and mortality. Biological mechanisms involved include generation of reactive oxygen species, inflammation and accelerated senescence. A better understanding of the vasotoxic effects of uremic retention molecules may reveal novel avenues to reduce vascular calcification in CKD. The present review aims to present a state of the art on the role of uremic toxins in pathogenesis of vascular calcification. Evidence, so far, is fragmentary and limited with only a few uremic toxins being investigated, often by a single group of investigators. Experimental heterogeneity furthermore hampers comparison. There is a clear need for a concerted action harmonizing and standardizing experimental protocols and combining efforts of basic and clinical researchers to solve the complex puzzle of uremic vascular calcification.
AB - The cardiorenal syndrome relates to the detrimental interplay between the vascular system and the kidney. The uremic milieu induced by reduced kidney function alters the phenotype of vascular smooth muscle cells (VSMC) and promotes vascular calcification, a condition which is strongly linked to cardiovascular morbidity and mortality. Biological mechanisms involved include generation of reactive oxygen species, inflammation and accelerated senescence. A better understanding of the vasotoxic effects of uremic retention molecules may reveal novel avenues to reduce vascular calcification in CKD. The present review aims to present a state of the art on the role of uremic toxins in pathogenesis of vascular calcification. Evidence, so far, is fragmentary and limited with only a few uremic toxins being investigated, often by a single group of investigators. Experimental heterogeneity furthermore hampers comparison. There is a clear need for a concerted action harmonizing and standardizing experimental protocols and combining efforts of basic and clinical researchers to solve the complex puzzle of uremic vascular calcification.
KW - uremic toxins
KW - uremia
KW - chronic kidney disease
KW - cardiovascular disease
KW - vascular smooth muscle cells
KW - vascular calcification
KW - middle molecules
KW - protein bound uremic solutes
KW - water-soluble uremic solutes
KW - SMOOTH-MUSCLE-CELLS
KW - CORONARY-ARTERY CALCIFICATION
KW - CHRONIC KIDNEY-DISEASE
KW - NF-KAPPA-B
KW - NECROSIS-FACTOR-ALPHA
KW - C-REACTIVE PROTEIN
KW - SERUM URIC-ACID
KW - PLASMA LEPTIN LEVELS
KW - GLYCATION END-PRODUCT
KW - INDOXYL SULFATE
U2 - 10.3390/toxins12100624
DO - 10.3390/toxins12100624
M3 - (Systematic) Review article
C2 - 33003628
SN - 2072-6651
VL - 12
JO - Toxins
JF - Toxins
IS - 10
M1 - 624
ER -